NO970317L - Anvendelse av DHA i en farmasöytisk blanding - Google Patents

Anvendelse av DHA i en farmasöytisk blanding

Info

Publication number
NO970317L
NO970317L NO970317A NO970317A NO970317L NO 970317 L NO970317 L NO 970317L NO 970317 A NO970317 A NO 970317A NO 970317 A NO970317 A NO 970317A NO 970317 L NO970317 L NO 970317L
Authority
NO
Norway
Prior art keywords
dha
pharmaceutical composition
fatty acids
essential fatty
dyslexic
Prior art date
Application number
NO970317A
Other languages
English (en)
Norwegian (no)
Other versions
NO970317D0 (no
Inventor
Barbara Jacqueline Stordy
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of NO970317D0 publication Critical patent/NO970317D0/no
Publication of NO970317L publication Critical patent/NO970317L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO970317A 1995-05-25 1997-01-24 Anvendelse av DHA i en farmasöytisk blanding NO970317L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment
PCT/GB1996/001265 WO1996037200A1 (en) 1995-05-25 1996-05-24 Use of dha as a pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO970317D0 NO970317D0 (no) 1997-01-24
NO970317L true NO970317L (no) 1997-01-24

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970317A NO970317L (no) 1995-05-25 1997-01-24 Anvendelse av DHA i en farmasöytisk blanding

Country Status (16)

Country Link
US (1) US6150411A (de)
EP (1) EP0774962B1 (de)
JP (1) JPH10503531A (de)
KR (1) KR970704433A (de)
AT (1) ATE264676T1 (de)
AU (1) AU722474B2 (de)
CA (1) CA2195979A1 (de)
DE (1) DE69632236T2 (de)
DK (1) DK0774962T3 (de)
ES (1) ES2217317T3 (de)
FI (1) FI970298A7 (de)
GB (1) GB9510636D0 (de)
NO (1) NO970317L (de)
PT (1) PT774962E (de)
WO (1) WO1996037200A1 (de)
ZA (1) ZA964215B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326344A (zh) * 1998-10-15 2001-12-12 Dsm公司 Pufa增补剂
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
EP1713463A4 (de) * 2004-01-19 2009-03-18 Martek Biosciences Corp Reelin-mangel oder dysfunktion und relevante verfahren
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
EP3335713B1 (de) 2009-10-29 2022-08-31 Acasti Pharma, Inc. Konzentrierte therapeutische phospholipid-zusammensetzungen
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
MX379148B (es) * 2016-06-01 2025-03-10 Soc Des Produits Nestle S A Star Composición para usar en la profilaxis de enfermedades alérgicas.
WO2023102170A1 (en) * 2021-12-02 2023-06-08 The Regents Of The University Of California Compositions and methods for inhibiting seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (de) * 1994-11-14 1997-11-26 Scotia Holdings Plc Mit GLA und/oder DGLA angereicherte Milch

Also Published As

Publication number Publication date
NO970317D0 (no) 1997-01-24
HK1012575A1 (en) 1999-08-06
DE69632236D1 (de) 2004-05-27
DK0774962T3 (da) 2004-08-09
FI970298L (fi) 1997-01-24
KR970704433A (ko) 1997-09-06
US6150411A (en) 2000-11-21
FI970298A0 (fi) 1997-01-24
AU5827796A (en) 1996-12-11
WO1996037200A1 (en) 1996-11-28
AU722474B2 (en) 2000-08-03
EP0774962A1 (de) 1997-05-28
CA2195979A1 (en) 1996-11-28
ZA964215B (en) 1996-12-04
JPH10503531A (ja) 1998-03-31
EP0774962B1 (de) 2004-04-21
ES2217317T3 (es) 2004-11-01
PT774962E (pt) 2004-09-30
FI970298A7 (fi) 1997-01-24
DE69632236T2 (de) 2005-04-14
GB9510636D0 (en) 1995-07-19
ATE264676T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
AU3402295A (en) Methods and means for drug administration
HUP0100970A2 (hu) Orálisan adagolható, azonnali és nyújtott hatóanyag felszabadítású, felszívódást elősegítő szert tartalmazó galenusi készítmény és ezen felszívódást elősegítő szer alkalmazása
EP1238677A3 (de) Parenterale Fettemulsionen, die EDTA als Konservierungsmittel enthalten
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
EP0343694A3 (en) Agent for the treatmment and protection of the skin
DE69111832D1 (de) Naproxen-Formulierung zur kontrollierten Absorption zur einmal täglichen Anwendung.
DE68928897D1 (de) Verfahren und system zur empfängnisverhütung
YU47899B (sh) Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
NO953874L (no) Farmasöytisk preparat inneholdende lipofile legemidler
AU2223095A (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
ATE194462T1 (de) Steigerung der kreatin und glykogen konzentration im muskel
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
EP0429522A4 (en) Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
AU1300001A (en) Gastroresistant tablets for alimentary, dietetic and therapeutic use
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
ATE110274T1 (de) Mittel zur verbesserung spezifischer eigenschaften des blutes.
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
ATE91079T1 (de) Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen.
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
JPH06263647A (ja) 過酸化脂質の抑制剤
MY114610A (en) Controlled drug delivery system for diltiazem.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application